TY - JOUR
T1 - Cyclophosphamide and Bone Marrow Transplantation
AU - Holcombe, Randall F.
AU - Rivera, Gaston K.
AU - Brochstein, Joel A.
PY - 1988/6/9
Y1 - 1988/6/9
N2 - To the Editor: In their article on allogeneic bone marrow transplantation in children, Brochstein et al. (Dec. 24 issue)1 comment that the conventional treatment with cyclophosphamide followed by total-body irradiation for cytoreduction before transplantation may not be as beneficial as the use of these same methods in the reverse order. It has been known for some time that there is an unacceptable graft-rejection rate of 25 to 60 percent after pretransplantation treatment with cyclophosphamide alone.2 For that reason, total-body irradiation in various dosages has been added to cyclophosphamide at most institutions as part of the conditioning regimen.34 Recently, I had.
AB - To the Editor: In their article on allogeneic bone marrow transplantation in children, Brochstein et al. (Dec. 24 issue)1 comment that the conventional treatment with cyclophosphamide followed by total-body irradiation for cytoreduction before transplantation may not be as beneficial as the use of these same methods in the reverse order. It has been known for some time that there is an unacceptable graft-rejection rate of 25 to 60 percent after pretransplantation treatment with cyclophosphamide alone.2 For that reason, total-body irradiation in various dosages has been added to cyclophosphamide at most institutions as part of the conditioning regimen.34 Recently, I had.
UR - https://www.scopus.com/pages/publications/0023909732
U2 - 10.1056/NEJM198806093182315
DO - 10.1056/NEJM198806093182315
M3 - Letter
C2 - 3285218
AN - SCOPUS:0023909732
SN - 0028-4793
VL - 318
SP - 1540
EP - 1542
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 23
ER -